Cargando…

Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis

IMPORTANCE: Commercial epicutaneous peanut immunotherapy (EPIT) and peanut oral immunotherapy (POIT) may offer significant quality-of-life improvements for patients with peanut allergy, but the cost-effectiveness of commercial peanut immunotherapies is uncharacterized. OBJECTIVE: To evaluate critica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaker, Marcus, Greenhawt, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503512/ https://www.ncbi.nlm.nih.gov/pubmed/31050778 http://dx.doi.org/10.1001/jamanetworkopen.2019.3242

Ejemplares similares

Determining Levers of Cost-effectiveness for Screening Infants at High Risk for Peanut Sensitization Before Early Peanut Introduction
por: Greenhawt, Matthew, et al.
Publicado: (2019)

Association of Fatality Risk With Value-Based Drug Pricing of Epinephrine Autoinjectors for Children With Peanut Allergy: A Cost-effectiveness Analysis
por: Shaker, Marcus, et al.
Publicado: (2018)

Simulation of Health and Economic Benefits of Extended Observation of Resolved Anaphylaxis
por: Shaker, Marcus, et al.
Publicado: (2019)

Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
por: Shaker, Marcus S., et al.
Publicado: (2022)

Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
por: Shaker, Marcus S., et al.
Publicado: (2020)

A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies
por: Shaker, Marcus, et al.
Publicado: (2021)

Peanut immunotherapy
por: Anagnostou, Katherine, et al.
Publicado: (2014)

Exploring barriers to commercial peanut oral immunotherapy treatment during COVID-19
por: Leef, Chelsea, et al.
Publicado: (2022)

Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care
por: Greenhawt, Matthew, et al.
Publicado: (2020)

Cost-effectiveness and Economic Benefit of Continuous Professional Development for Drug Prescribing: A Systematic Review
por: Cook, David A., et al.
Publicado: (2022)

Genotypic Characterization of the U.S. Peanut Core Collection
por: Otyama, Paul I., et al.
Publicado: (2020)

Peanut Immunotherapy: Stepping Towards Desensitization for Peanut Allergy
por: Hsu, Joyce
Publicado: (2020)

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
por: Fleischer, David M., et al.
Publicado: (2015)

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
por: Fleischer, David M., et al.
Publicado: (2015)

Cost of Inpatient Falls and Cost-Benefit Analysis of Implementation of an Evidence-Based Fall Prevention Program
por: Dykes, Patricia C., et al.
Publicado: (2023)

The Use of SNP Markers for Linkage Mapping in Diploid and Tetraploid Peanuts
por: Bertioli, David J., et al.
Publicado: (2013)

Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers
por: Gallop, Katy, et al.
Publicado: (2022)

Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050
por: Chen, Simiao, et al.
Publicado: (2023)

A Practical, Stepwise Approach to Peanut Oral Immunotherapy in Clinical Practice: Benefits and Risks
por: Anagnostou, Aikaterini
Publicado: (2021)

What the COVID-19 Pandemic Can Teach Us About Resource Stewardship and Quality in Health Care
por: Abrams, Elissa M., et al.
Publicado: (2021)

School Attendance, Asthma Risk, and COVID-19 in Children
por: Abrams, Elissa M., et al.
Publicado: (2021)

Allergists Can Safely Evaluate and Revaccinate Individuals With Immediate Allergic Reactions to mRNA COVID-19 Vaccines
por: Greenhawt, Matthew, et al.
Publicado: (2021)

COVID-19 and the importance of effective risk communication with children
por: Abrams, Elissa M, et al.
Publicado: (2022)

Pod and Seed Trait QTL Identification To Assist Breeding for Peanut Market Preferences
por: Chavarro, Carolina, et al.
Publicado: (2020)

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma
por: Bateni, Sarah B., et al.
Publicado: (2023)

Benefits of Dominance over Additive Models for the Estimation of Average Effects in the Presence of Dominance
por: Duenk, Pascal, et al.
Publicado: (2017)

PEG/Polysorbate Skin Testing Has No Utility in the Assessment of Suspected Allergic Reactions to SARS-CoV-2 Vaccines
por: Greenhawt, Matthew, et al.
Publicado: (2021)

Deriving health utility indices from a food allergy quality‐of‐life questionnaire
por: Chen, Gang, et al.
Publicado: (2021)

Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018)

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A., et al.
Publicado: (2020)

Peanut oral immunotherapy may improve health‐related quality of life among severe peanut allergic adolescents
por: Ödling, Maria, et al.
Publicado: (2023)

COVID-19 vaccines: addressing hesitancy in young people with allergies
por: Abrams, Elissa M, et al.
Publicado: (2021)

Genetic Mapping of Resistance to Meloidogyne arenaria in Arachis stenosperma: A New Source of Nematode Resistance for Peanut
por: Leal-Bertioli, Soraya C. M., et al.
Publicado: (2015)

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
por: Goldstein, Daniel A., et al.
Publicado: (2023)

Mapping the Economic Costs and Benefits of Conservation
por: Naidoo, Robin, et al.
Publicado: (2006)

Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
por: Culyer, Anthony J., et al.
Publicado: (2019)

First results of MIRABEL: a research program to develop tools for risk and cost/benefit analysis of peanut allergy
por: Crépet, A, et al.
Publicado: (2013)

Contemporary economic burden in a real‐world heart failure population with Commercial and Medicare supplemental plans
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

The COVID-19 pandemic: Adverse effects on the social determinants of health in children and families
por: Abrams, Elissa M., et al.
Publicado: (2022)

Assessment of Pediatrician Awareness and Implementation of the Addendum Guidelines for the Prevention of Peanut Allergy in the United States
por: Gupta, Ruchi S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nhoabdv44qmj4spe1mt5sneqqb